支持PROTAC开发的最新进展,以解决针对瘤的瘤毒性
Chuanjie Chen1,2, Yiwen Yang3, Zhe Wang3
1Drug Discovery & Development Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Journal of medicinal chemistry
|June 15, 2023
概括
向蛋白质分解的仿真体 (PROTACs) 提供向蛋白质降解,但面临着向瘤外的毒性. 基于原药的PROTACs (pro-PROTACs) 正在出现,以增强瘤特异性输送并最大限度地减少副作用.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 化向化体 (PROTAC) 技术使得向蛋白质降解成为可能.
- 在治疗包括癌症在内的各种疾病方面,PROTACs显得有前途.
- 针对健康细胞的瘤外毒性是PROTAC临床应用的一个重大挑战.
研究的目的:
- 要突出创新的策略来增强细胞选择性PROTAC活动.
- 讨论针对瘤的向释放的基于前期药物的PROTACs (支持PROTACs).
- 探索 PROTAC 支持者在扩大 PROTAC 技术应用中的潜力.
主要方法:
- 审查关于PROTAC技术的当前研究.
- 分析实现细胞选择性蛋白质降解的策略.
- 探索用于有针对性的PROTAC输送的前期药物方法.
主要成果:
- 基于原药的PROTACs (pro-PROTACs) 提供了一种针对瘤的释放策略.
- 这些方法旨在最大限度地降低点上,瘤外毒性.
- 支持PROTAC的人可能会扩大PROTAC技术的治疗应用.
结论:
- 创新的前药物策略对于基于PROTAC的安全有效的癌症治疗至关重要.
- 支持PROTACs在向蛋白质降解方面是一个有希望的进步.
- 支持PROTACs的进一步开发可能会对药物开发和临床结果产生重大影响.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:27Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
01:26Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K